Research
Energy balance
The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.
Semaglutide may lead to significant weight loss in patients with MASH.
StrongSupportsmedium confidence
The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.
Why this rating
Based on the large randomized controlled trial design.
Source
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Arun J. Sanyal et al. · New England Journal of Medicine · 2025
rct · n=1197Cited 618×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →